In last year’s edition of our report, Commercial Trends for Biomarker-Based IVD Tests, we predicted growth in multiplex biomarker tests, and we can now report that tests cleared during 2013 support this prediction. Over half of all biomarker-based tests cleared...
Interesting point regarding alternative to gene patenting for diagnostics: assay patenting instead. “In the drug space, people have very clearly figured out that the most airtight patents are around the molecules themselves,” says SV Bio’s Stephan. “Even if that...